Clinical Trial Update: Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating autologous/allogeneic TGF-beta-resistant LMP-specific cytotoxic T lymphocytes for lymphoma; the study is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Autologous/Allogeneic TGF-beta-resistant LMP-specific CTLs

Snippet

Sponsor: Baylor College of Medicine | Conditions: Lymphoma, Hodgkin's Disease | Phase 1 | Status: ACTIVE_NOT_RECRUITING